{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:20:30Z","timestamp":1772857230258,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004182","name":"Nordic Council of Ministers","doi-asserted-by":"publisher","award":["85352"],"award-info":[{"award-number":["85352"]}],"id":[{"id":"10.13039\/501100004182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejps.2025.107397","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:32:37Z","timestamp":1764865957000},"page":"107397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synthesis, in vitro characterization and biopharmaceutical evaluation of a novel phosphate prodrug of sorafenib"],"prefix":"10.1016","volume":"217","author":[{"given":"Simon Hoang","family":"Dinh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Ding","family":"Fisker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juulia","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kati-Sisko","family":"Vellonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bauer-Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poul","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Rautio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-5016","authenticated-orcid":false,"given":"Martin","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejps.2025.107397_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"issue":"39","key":"10.1016\/j.ejps.2025.107397_bib0002","doi-asserted-by":"crossref","first-page":"27244","DOI":"10.1039\/D3RA03867J","article-title":"Enhancing solubility and stability of sorafenib through cyclodextrin-based inclusion complexation: in silico and in vitro studies [10.1039\/D3RA03867J]","volume":"13","author":"Aman","year":"2023","journal-title":"RSC Adv."},{"issue":"3","key":"10.1016\/j.ejps.2025.107397_bib0003","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ejps.2025.107397_bib0004","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1023\/A:1026402410783","article-title":"The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds","volume":"17","author":"Aungst","year":"2000","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2025.107397_bib0006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijpharm.2006.12.011","article-title":"In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation","volume":"336","author":"Brouwers","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ejps.2025.107397_bib0007","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s11095-007-9307-3","article-title":"Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of Fosamprenavir in the fasted and fed State","volume":"24","author":"Brouwers","year":"2007","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejps.2025.107397_bib0005","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107397_bib51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejps.2018.04.031","article-title":"Co-existing colloidal phases in artificial intestinal fluids assessed by AF4\/MALLS and DLS: A systematic study into cholate & (lyso-) phospholipid blends, incorporating celecoxib as a model drug","volume":"120","author":"Elvang","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107397_bib0008","article-title":"Impact of prandial state on luminal and permeation-behavior of fosamprenavir oral suspension studied by in vitro tools: solubility-, bioconversion- and permeation- studies in biomimetic media","volume":"90","author":"Eriksen","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejps.2025.107397_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106366","article-title":"In-vitro dynamic dissolution\/bioconversion\/permeation of fosamprenavir using a novel tool with an artificial biomimetic permeation barrier and microdialysis-sampling","volume":"181","author":"Eriksen","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2025.107397_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2019.1559058","article-title":"Sorafenib: key lessons from over 10 years of experience","volume":"19","author":"Escudier","year":"2019","journal-title":"Expert. Rev. AntiCancer Ther."},{"issue":"8","key":"10.1016\/j.ejps.2025.107397_bib0011","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/009127002401102803","article-title":"Pharmacokinetics of GW433908, a prodrug of Amprenavir, in healthy male volunteers","volume":"42","author":"Falcoz","year":"2002","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107397_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jss.2015.12.008","article-title":"Intestinal alkaline phosphatase: a summary of its role in clinical disease","volume":"202","author":"Fawley","year":"2016","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ejps.2025.107397_bib0013","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0076-6879(85)12030-6","article-title":"Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting","volume":"112","author":"Fleisher","year":"1985","journal-title":"Methods Enzym."},{"key":"10.1016\/j.ejps.2025.107397_bib0014","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejps.2016.09.018","article-title":"A novel microdialysis-dissolution\/permeation system for testing oral dosage forms: a proof-of-concept study","volume":"96","author":"Fong","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ejps.2025.107397_bib0015","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/dmd.110.032052","article-title":"In vitro to In vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein","volume":"38","author":"Gnoth","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.ejps.2025.107397_bib0016","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","article-title":"Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories","volume":"35","author":"Hayeshi","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2025.107397_bib0017","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1023\/A:1023827017224","article-title":"Absorption rate limit considerations for oral phosphate prodrugs","volume":"20","author":"Heimbach","year":"2003","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2025.107397_bib0018","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-5173(03)00287-4","article-title":"Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs","volume":"261","author":"Heimbach","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107397_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106166","article-title":"Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid-associated drug concentrations during biomimetic dissolution testing of supersaturating formulations","volume":"174","author":"Holzem","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2025.107397_bib0019","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.xphs.2024.07.017","article-title":"Oral absorption from surfactant-based drug formulations: the impact of molecularly dissolved drug on bioavailability","volume":"113","author":"Holzem","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2025.107397_bib0021","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/cancers12113322","article-title":"Epithelial transfer of the tyrosine kinase inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: implications for clinical resistance","volume":"12","author":"Honeywell","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ejps.2025.107397_bib0022","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"issue":"6","key":"10.1016\/j.ejps.2025.107397_bib0023","first-page":"153","article-title":"Implementation of the Caco-2 cell culture modelas a predictive tool for the oral absorption of drugs. In-house evaluation procedures [Article]","volume":"57","author":"Ingels","year":"2002","journal-title":"J. Pharm. Belg."},{"issue":"1","key":"10.1016\/j.ejps.2025.107397_bib0024","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(01)00897-3","article-title":"Simulated intestinal fluid as transport medium in the Caco-2 cell culture model","volume":"232","author":"Ingels","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2025.107397_bib0025","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/pharmaceutics15020592","article-title":"Commercially available cell-free permeability tests for industrial drug development: increased sustainability through reduction of In vivo studies","volume":"15","author":"Jacobsen","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ejps.2025.107397_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","article-title":"The use of biorelevant dissolution media to forecast the in vivo performance of a drug","volume":"12","author":"Klein","year":"2010","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.ejps.2025.107397_bib0027","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1021\/acs.jcim.5b00255","article-title":"Critically assessing the predictive power of QSAR models for Human liver microsomal stability","volume":"55","author":"Liu","year":"2015","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.ejps.2025.107397_bib0026","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","article-title":"Improving oral bioavailability of Sorafenib by optimizing the \u201cSpring\u201d and \u201cParachute\u201d based on molecular interaction mechanisms","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2025.107397_bib0028","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00280-020-04065-5","article-title":"Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study","volume":"85","author":"Mammatas","year":"2020","journal-title":"Cancer Chemother Pharmacol."},{"issue":"12","key":"10.1016\/j.ejps.2025.107397_bib0029","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3390\/pharmaceutics15122691","article-title":"The development of lipid-based sorafenib granules to enhance the oral absorption of Sorafenib","volume":"15","author":"Mans","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.ejps.2025.107397_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111031","article-title":"Prodrugs for improved drug delivery: lessons learned from recently developed and marketed products","volume":"12","author":"Markovic","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107397_bib0031","unstructured":"Nexavar: EPAR - Product information. (2009). European medicines agency committee for medicinal products for human use (CHMP) Retrieved from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexavar."},{"key":"10.1016\/j.ejps.2025.107397_bib0032","unstructured":"Nexavar: EPAR - Scientific Discussion. (2007). European medicines agency committee for medicinal products for human use (CHMP) Retrieved from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexavar."},{"issue":"4","key":"10.1016\/j.ejps.2025.107397_bib0034","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jphp.12957","article-title":"Food for thought: formulating away the food effect - a PEARRL review","volume":"71","author":"O'Shea","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107397_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106098","article-title":"Best practices in current models mimicking drug permeability in the gastrointestinal tract - an UNGAP review","volume":"170","author":"O'Shea","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107397_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100103","article-title":"Sorafenib tosylate novel drug delivery systems: implications of nanotechnology in both approved and unapproved indications","volume":"8","author":"Raut","year":"2022","journal-title":"OpenNano"},{"issue":"8","key":"10.1016\/j.ejps.2025.107397_bib0036","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejps.2025.107397_bib0041","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2478\/acph-2019-0024","article-title":"Metabolic stability and its role in the discovery of new chemical entities","volume":"69","author":"S\u0142oczy\u0144ska","year":"2019","journal-title":"Acta Pharm."},{"key":"10.1016\/j.ejps.2025.107397_bib0037","unstructured":"Safety Testing of Drug Metabolites - Guidance for Industry. (2020). U.S. food & drug administration Retrieved from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-testing-drug-metabolites."},{"issue":"3","key":"10.1016\/j.ejps.2025.107397_bib0038","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0939-6411(00)00113-2","article-title":"Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers","volume":"50","author":"Saha","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2025.107397_bib0039","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2014.04.012","article-title":"An improved method for the characterization of supersaturation and precipitation of poorly soluble drugs using pulsatile microdialysis (PMD)","volume":"468","author":"Shah","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2025.107397_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13321-020-00426-7","article-title":"Predicting liver cytosol stability of small molecules","volume":"12","author":"Shah","year":"2020","journal-title":"J. Cheminform."},{"key":"10.1016\/j.ejps.2025.107397_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121216","article-title":"Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion","volume":"610","author":"Song","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejps.2025.107397_bib0043","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1039\/D2CS00957A","article-title":"Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates [10.1039\/D2CS00957A]","volume":"53","author":"Subbaiah","year":"2024","journal-title":"Chem. Soc. Rev."},{"issue":"1 Pt 1","key":"10.1016\/j.ejps.2025.107397_bib0044","article-title":"Intestinal alkaline phosphatase is secreted bidirectionally from villous enterocytes","volume":"257","author":"Sussman","year":"1989","journal-title":"Am. J. Physiol."},{"issue":"3","key":"10.1016\/j.ejps.2025.107397_bib0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1208\/pt040345","article-title":"Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir","volume":"4","author":"Tirucherai","year":"2003","journal-title":"AAPS. PharmSciTech."},{"key":"10.1016\/j.ejps.2025.107397_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123654","article-title":"Enzymatic prodrug degradation in the fasted and fed small intestine: in vitro studies and interindividual variability in human aspirates","volume":"649","author":"Vinarov","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.ejps.2025.107397_bib0047","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2025.107397_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/128_2014_561","article-title":"Prodrugs of phosphonates and phosphates: crossing the membrane barrier","volume":"360","author":"Wiemer","year":"2015","journal-title":"Top Curr. Chem."},{"issue":"10","key":"10.1016\/j.ejps.2025.107397_bib0048","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2025.107397_bib0049","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200645020-00002","article-title":"Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug","volume":"45","author":"Wire","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.ejps.2025.107397_bib0050","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1124\/dmd.108.026245","article-title":"Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs","volume":"37","author":"Yuan","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500394X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500394X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:09:22Z","timestamp":1768392562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872500394X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":53,"alternative-id":["S092809872500394X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107397","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, in vitro characterization and biopharmaceutical evaluation of a novel phosphate prodrug of sorafenib","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107397"}}